Smolen JS, et al. - This study provides insight into the safety, immunogenicity and efficacy after switching from reference infliximab (INF) to biosimilar SB2 (a biosimilar of reference INF), compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis (RA). Findings demonstrated that up to week 78, the INF/SB2, INF/INF and SB2/SB2 groups exhibited comparable efficacy, safety and immunogenicity profiles, with no treatment-emergent issues or clinically relevant immunogenicity observed after switching from INF to SB2.